Lunit, Summit to evaluate pathology platform for tumour analysis

Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing the tumour microenvironment across immuno-oncology programmes evaluating ivonescimab. Lunit will examine haematoxylin and eosin-stained whole-slide images to profile tumour microenvironment characteristics. The companies plan to utilise Lunit SCOPE IO to identify biomarkers, stratify patients, and investigate biological responses to ivonescimab. Credit: Gorodenkoff / Shutterstock.com. Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing the tumour microenvironment across immuno-oncology programmes evaluating ivonescimab. Under the partnership, the platform will be applied…

Source: Pharmaceutical Technology